TITLE

Trace Amounts of Microbe-Killing Molecules Predict Chronic Granulomatous Disease Survival

PUB. DATE
July 2011
SOURCE
International Journal of Virology;2011, Vol. 7 Issue 2, p74
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
65418214

 

Related Articles

  • Squaring HIV's vicious circle. Day, Michael // New Scientist;5/25/96, Vol. 150 Issue 2031, p17 

    Focuses on the effect of HIV viruses on the immune system according to findings from researchers at the United States National Institutes of Allergy & Infectious Diseases (NIAID). Microorganisms causing an increase in the amount of HIV viruses; Action of the immune system weakened by invading...

  • This puzle known as primary immunodefeciency. Magill-Lewis, Jillene // Drug Topics;1/26/2004, Vol. 148 Issue 2, pHSE22 

    Provides an educational information about primary immunodeficiency (PI) based on the study conducted by the National Institute of Allergy and Infectious Diseases in the U.S. Presentation of PI in adults; Delay of diagnosis; Development of autoimmune disorders.

  • NIAID workshop on immunity to malaria: addressing immunological challenges. Augustine, Alison Deckhut; Hall, B. Fenton; Leitner, Wolfgang W.; Mo, Annie X.; Wali, Tonu M.; Fauci, Anthony S. // Nature Immunology;Jul2009, Vol. 10 Issue 7, p673 

    In this article the authors discuss the U.S. National Institute of Allergy and Infectious Disease workshop held on March 16-17, 2009. They state that the workshops highlights the gaps in the immunology research and emphasizes the basic immune mechanisms that could protect that people against...

  • New Guidelines Are Aimed At Allergy Sufferers. Moore, Amy Slugg // RN;May2000, Vol. 63 Issue 5, p18 

    Reports that the American Academy of Allergy, Asthma and Immunology, in partnership with the United States National Institute of Allergy and Infectious Diseases and other medical groups have created a comprehensive medical guideline aimed at allergy sufferers. Availability of copies of the...

  • NIAID amps up vaccine adjuvant work. Mullard, Asher // Nature Reviews Drug Discovery;Nov2014, Vol. 13 Issue 11, p803 

    The article reports on the plan of the U.S. National Institute of Allergy and Infectious Diseases (NIAID) to spend up to $70 million for the development of vaccine adjuvants.

  • Northrop Grumman, UTSW Boost Biodefense Resources. Withrow, Steven // Bio-IT World;Feb2006, Vol. 5 Issue 1, p34 

    Presents information on the Immunology Database and Analysis Portal contract, also known as the ImmPort, awarded by the U.S. National Institute of Allergy and Infectious Diseases to Northrop Grumman's information technology sector in September 2004. Focus of the ImmPort; Goals of the ImmPort;...

  • Immune deficiency disease research.  // Presidents & Prime Ministers;Jul/Aug95, Vol. 4 Issue 4, p34 

    Reports on the partnership of the National Institute of Allergy and Infectious Diseases (NIAID) and the Jeffrey Modell Foundation to further research on primary immune deficiency diseases. Estimated number of affected Americans; Anthony S. Fauci, director of NIAID.

  • Scientists Turn to Immune "Fingerprints" to Understand Vaccines, Infections. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;12/8/2010, Vol. 304 Issue 22, p2470 

    The article offers information on the human immune phenotyping initiative launched by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) in December 2010. Said initiative is in response to efforts in identifying human immune responses like the production of antibodies to...

  • NIH AWARDS SEVEN NEW VACCINE ADJUVANT DISCOVERY CONTRACTS.  // HS Today;Oct/Nov2014, Vol. 11 Issue 6, p18 

    The article reports that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded several research contracts for the development of adjuvants.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics